Ann: VIT enters into Scheme Implementation Deed-VIT.AX, page-176

Data Room article from the Australian. Time will tell whether a second bidder will emerge

While it’s known that Shanghai Pharma was the underbidder to Biostime for Swisse Wellness last year, what was not known was that the company offered the same price as its Hong Kong owner Biostime. Apparently, the deal breaker was that Shanghai Pharma required more time for the transaction to be finalised.
The emergence of the details of last year’s fight for the vitamin group are interesting, given Shanghai Pharma is now bidding $314m for Vitaco.
It suggests that Shanghai Pharma, backed by the Chinese government, has the firepower to blow any suitor out of the water should a rival bid emerge.
Given the money it was prepared to pay for Swisse, it would take a game competitor to trigger a bidding war.
Meanwhile, sources are questioning the level of interest for the vitamins business Nature’s Care, claiming it has limited appeal to Chinese parties — the ones prepared to pay large prices for vitamin groups. Some were said to be taken back by the original price expectations, thought to be around $1bn.